Recent federal actions are clearly having significant impacts on the fields of science and medicine. SITC is working closely with our trusted government consultant in Washington, DC to stay informed on the rapidly shifting landscape. We are actively participating in Hill visits to communicate the catastrophic downstream impact of the delays in NCI funding on the biomedical research ecosystem. One of our most effective tools is congressional advocacy. We encourage you to utilize the
advocacy tools we have assembled. Sending a pre-written message (a simple copy/paste from our tools webpage) to your congressional delegates takes just a few minutes—and it can have a meaningful impact.
In these challenging times, SITC remains steadfast in its mission to advance powerful immunotherapies for all cancer patients. We continue to provide valuable immuno-oncology (IO) resources and events that support our members in pursuing groundbreaking research, training the next generation of IO researchers and clinicians, and improving patient outcomes with innovative and more effective therapies.
It goes without saying that our members are the heart of SITC. Over the past four decades, we have built a diverse and resilient community. Now, more than ever, it is essential to stay connected to the SITC family as a reliable network in these rapidly evolving times. We’ve been hearing firsthand about the significant professional challenges these changes are creating, particularly for early-career scientists. Based on these conversations, we are developing a series of virtual town halls to support our community. Stay tuned for additional information about this program.
In addition, if you are attending professional events in the coming months, we invite you to connect with SITC in person so we can best understand how to support you. Visit us in the exhibit hall at the following conferences:
Oncology Nursing Society Congress (ONS) — April 10–12
American Association of Cancer Research (AACR) — April 27–30
American Society of Clinical Oncology (ASCO) — May 31–June 2
The work you do is vital, and we are grateful for your dedication. SITC stands with you—and we appreciate you.
Leisha A. Emens, MD, PhD
SITC Immidiate Past & Acting President
|
Program Spotlight
|
|
Advances in Cancer Immunotherapy™ (ACI)
|
|
SITC’s ACIs offer in-depth clinical training in immunotherapy treatment for a variety of disease states and emerging IO therapeutic modalities! The 2025 series feature nine topic-driven virtual programs (approximately 4 hours long) offering CME, CNE, CPE, or MOC credit. Three in-person sessions are also scheduled and hosted at subspecialty meetings.
|
|
|
Deep Dive Webinar Series
|
|
This is a series of highly focused webinars designed to dive deep into the current science behind hot topics in immuno-oncology. The webinar series – co-chaired by Mario Sznol, MD – Yale School of Medicine and Daniel S. Chen, MD, PhD – Synthetic Design Lab – features topics including: Vivo gene modification as a method of generating CAR-T cells and more.
|
|
What's New at the Journal for ImmunoTherapy of Cancer (JITC)
|
|
|
|
Additional Programming and Events
|
|
|